176
Participants
Start Date
October 31, 2001
Primary Completion Date
August 31, 2006
Study Completion Date
May 31, 2015
Control
Autologous cellular product consisting of antigen presenting cells (APCs) prepared in the absence of PA2024 antigen.
Sipuleucel-T
Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
Mount Sinai School of Medicine, New York
Urology Health Specialists - Bryn Mawr, Bryn Mawr
Bryn Mawr Urology Group, Rosemont
Albert Einstein Medical Building, Philadelphia
Urology of Virginia, PC, Virginia Beach
McKay Urology, Charlotte
University of Tennessee, Memphis
AKSM Clinical Research Group, Columbus
South Orange County Medical Research, Laguna Hills
Alta Bates Comprehensive Cancer Center, Berkeley
Providence Medical Center, Portland
Oregon Health and Sciences University, Portland
Oregon Urology Institute, Springfield
Virginia Mason Medical Center, Seattle
Swedish Medical Center, Seattle
University of Colorado Health Sciences Center, Aurora
Oncology Specialists, SC, Park Ridge
University of Rochester Medical Center, Rochester
Lead Sponsor
Dendreon
INDUSTRY